182 related articles for article (PubMed ID: 28994314)
1. Preventing liver fibrosis in patients with NAFLD and the road ahead.
Nobili V; Miele L; Alisi A
Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1081-1083. PubMed ID: 28994314
[No Abstract] [Full Text] [Related]
2. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease.
Panera N; Gnani D; Crudele A; Ceccarelli S; Nobili V; Alisi A
World J Gastroenterol; 2014 Nov; 20(41):15079-86. PubMed ID: 25386056
[TBL] [Abstract][Full Text] [Related]
3. Future trends in the treatment of non-alcoholic steatohepatitis.
Fiorucci S; Biagioli M; Distrutti E
Pharmacol Res; 2018 Aug; 134():289-298. PubMed ID: 30021122
[TBL] [Abstract][Full Text] [Related]
4. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.
Fuchs CD; Traussnigg SA; Trauner M
Semin Liver Dis; 2016 Feb; 36(1):69-86. PubMed ID: 26870934
[TBL] [Abstract][Full Text] [Related]
5. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
6. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges.
Goldner D; Lavine JE
Gastroenterology; 2020 May; 158(7):1967-1983.e1. PubMed ID: 32201176
[TBL] [Abstract][Full Text] [Related]
8. Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.
Wree A; Mehal WZ; Feldstein AE
Semin Liver Dis; 2016 Feb; 36(1):27-36. PubMed ID: 26870930
[TBL] [Abstract][Full Text] [Related]
9. Fatty liver disease.
Brody H
Nature; 2017 Nov; 551(7681):. PubMed ID: 29168811
[No Abstract] [Full Text] [Related]
10. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease.
Orlic L; Mikolasevic I; Lukenda V; Anic K; Jelic I; Racki S
Wien Klin Wochenschr; 2015 May; 127(9-10):355-62. PubMed ID: 25412597
[TBL] [Abstract][Full Text] [Related]
12. 13C-Methacetin Breath Testing in Patients with Non-Alcoholic Fatty Liver Disease.
Kempiński R; Neubauer K; Wieczorek S; Dudkowiak R; Jasińska M; Poniewierka E
Adv Clin Exp Med; 2016; 25(1):77-81. PubMed ID: 26935501
[TBL] [Abstract][Full Text] [Related]
13. Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.
Athyros VG; Katsiki N; Doumas M
Curr Vasc Pharmacol; 2018 Jan; 16(2):104-106. PubMed ID: 29210655
[No Abstract] [Full Text] [Related]
14. Review. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease.
Sun X; Zhang Y; Xie M
Acta Pharm; 2017 Mar; 67(1):1-13. PubMed ID: 28231052
[TBL] [Abstract][Full Text] [Related]
15. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
[TBL] [Abstract][Full Text] [Related]
16. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
Stål P
World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
[TBL] [Abstract][Full Text] [Related]
17. How to Approach a Patient With Nonalcoholic Fatty Liver Disease.
Tilg H
Gastroenterology; 2017 Aug; 153(2):345-349. PubMed ID: 28647352
[No Abstract] [Full Text] [Related]
18. Mouse models of nonalcoholic steatohepatitis in preclinical drug development.
Hansen HH; Feigh M; Veidal SS; Rigbolt KT; Vrang N; Fosgerau K
Drug Discov Today; 2017 Nov; 22(11):1707-1718. PubMed ID: 28687459
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
20. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV.
Verna EC
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):211-223. PubMed ID: 28404136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
